Tianjin Life Science & Technology Co., Ltd. announces that its Glipizide Controlled-Release Tablets (5mg) have received approval for market launch from the National Medical Products Administration. This approval expands the company's endocrine product line and enhances market competitiveness. The drug is classified as a Category 4 chemical drug, considered equivalent to a first-time approval.
Summary generated by AI · Always verify with source document
Securities Code: 002393 Securities Abbreviation: Life Science Pharmaceutical Announcement Number: 2026-037
Tianjin Life Science & Technology Co., Ltd. Announcement on the Approval of Glipizide Controlled-Release Tablets for Market Launch
The company and all members of the board of directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Overview
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.